Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/46790
DC FieldValueLanguage
dc.contributor.authorBoronat, Mauroen_US
dc.contributor.authorGarcía-Cantón, Césaren_US
dc.contributor.authorLópez-Ríos, Lauraen_US
dc.contributor.authorQuevedo, Virginiaen_US
dc.contributor.authorLorenzo, Dionisio L.en_US
dc.contributor.authorBatista, Fátimaen_US
dc.contributor.authorRiaño, Martaen_US
dc.contributor.authorNóvoa, Francisco J.en_US
dc.date.accessioned2018-11-23T08:13:16Z-
dc.date.available2018-11-23T08:13:16Z-
dc.date.issued2014en_US
dc.identifier.issn1479-1641en_US
dc.identifier.urihttp://hdl.handle.net/10553/46790-
dc.description.abstractThis study analyses discordance rates between attainment of therapeutic goals for apolipoprotein B100 (apoB) and both low-density lipoprotein-cholesterol (LDL-C) and non-high-density lipoprotein-cholesterol (non-HDL-C) in a sample of 152 patients with type 2 diabetes and chronic kidney disease from Gran Canaria (Spain), using treatment targets recommended by the American Diabetes Association/American College of Cardiology (ADA/ACC), the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) and by a Spanish population-based study. Among subjects with LDL-C levels at therapeutic goal, apoB was above target in 16.3% (ADA/ACC), 6.5% (ESC/EAS) and 39.1% (population-based criteria), and among subjects with non-HDL-C levels at therapeutic goal, apoB was above target in 10.5% (ADA/ACC), 1.2% (ESC/EAS) and 29.6% (population-based criteria). These findings show that clinical management would be very differently altered depending on the criteria used to set treatment targets for apoB. Cut-off points derived from population data identify a greater number of subjects suitable for a more intensive lipid-lowering therapy.en_US
dc.languageengen_US
dc.relation.ispartofDiabetes and Vascular Disease Researchen_US
dc.sourceDiabetes and Vascular Disease Research [ISSN 1479-1641],v. 11, p. 53-59en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject.otherApolipoprotein B100,en_US
dc.subject.otherLow-density lipoprotein–cholesterolen_US
dc.subject.otherNon-high-density lipoprotein–cholesterolen_US
dc.subject.otherCardiovascular risken_US
dc.subject.otherLipid goalsen_US
dc.subject.otherType 2 diabetesen_US
dc.titlePotential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney diseaseen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1177/1479164113511834en_US
dc.identifier.scopus84890453908-
dc.identifier.isi000328315700009-
dc.contributor.authorscopusid7003952293-
dc.contributor.authorscopusid6603127359-
dc.contributor.authorscopusid33068166900-
dc.contributor.authorscopusid50561862600-
dc.contributor.authorscopusid55967938300-
dc.contributor.authorscopusid55968288300-
dc.contributor.authorscopusid37067926100-
dc.contributor.authorscopusid12786120600-
dc.description.lastpage59en_US
dc.description.firstpage53en_US
dc.relation.volume11en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid673494-
dc.contributor.daisngid1915819-
dc.contributor.daisngid1964185-
dc.contributor.daisngid5112593-
dc.contributor.daisngid30519221-
dc.contributor.daisngid5867919-
dc.contributor.daisngid5257474-
dc.contributor.daisngid556390-
dc.description.numberofpages7en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Boronat, M-
dc.contributor.wosstandardWOS:Garcia-Canton, C-
dc.contributor.wosstandardWOS:Lopez-Rios, L-
dc.contributor.wosstandardWOS:Quevedo, V-
dc.contributor.wosstandardWOS:Lorenzo, DL-
dc.contributor.wosstandardWOS:Batista, F-
dc.contributor.wosstandardWOS:Riano, M-
dc.contributor.wosstandardWOS:Novoa, FJ-
dc.date.coverdateEnero 2014en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,202
dc.description.jcr2,829
dc.description.sjrqQ1
dc.description.jcrqQ2
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0001-8535-8543-
crisitem.author.orcid0000-0002-5988-8222-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameBoronat Cortés, Mauro-
crisitem.author.fullNameGarcía Cantón, César-
crisitem.author.fullNameLorenzo Villegas, Dionisio Lorenzo-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

3
checked on Nov 3, 2024

WEB OF SCIENCETM
Citations

3
checked on Nov 3, 2024

Page view(s)

37
checked on Feb 25, 2023

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.